```html

Oesophageal Varices – A Complete Medical Guide

Overview

Oesophageal varices are enlarged, thin‑walled veins that develop in the lining of the lower part of the esophagus (the tube that carries food from the mouth to the stomach). They develop as a consequence of increased pressure in the portal venous system — a condition called portal hypertension. While the varices themselves are not painful, they are fragile and can rupture, leading to life‑threatening bleeding.

Who it affects

• Adults with chronic liver disease, especially cirrhosis (the most common cause).
• Patients with portal hypertension from non‑cirrhotic causes (e.g., schistosomiasis, portal vein thrombosis).
• Less commonly, children with congenital liver disease may develop varices.

Prevalence

• Up to 50–60 % of patients with compensated cirrhosis develop oesophageal varices within 2–3 years of diagnosis.<sup>1</sup>
• Bleeding from varices occurs in roughly 10–15 % of cirrhotic patients per year, and it accounts for 30–40 % of all upper‑GI bleeding in this population.<sup>2</sup>
• In the United States, an estimated 4–5 million people have chronic liver disease; of these, roughly 1 million are at risk for variceal bleeding.<sup>3</sup>

Symptoms

Many patients with oesophageal varices are asymptomatic until a bleed occurs. When symptoms appear, they can be vague or sudden.

Prior to bleeding

• Occult (hidden) blood loss – may cause mild anemia, fatigue, or weakness.
• Upper‑abdominal discomfort – a feeling of fullness or pressure, especially after meals.
• Glossy “water‑bruising” (spider telangiectasias) on the skin – a sign of underlying portal hypertension.

Bleeding (acute presentation)

• Vomiting of fresh (bright red) blood (hematemesis) or “coffee‑ground” material indicating partially digested blood.
• Melena – black, tarry stools caused by digested blood.
• Hematemesis with shock signs – dizziness, rapid heartbeat, low blood pressure, cold clammy skin.
• Sudden drop in hemoglobin on laboratory testing.
• Chest or back pain – can mimic cardiac events; always evaluated in the emergency department.

Causes and Risk Factors

The root cause is portal hypertension. The most common upstream conditions are:

• Cirrhosis (≈90 % of cases) – caused by chronic alcohol use, viral hepatitis B or C, non‑alcoholic fatty liver disease (NAFLD), and autoimmune liver diseases.
• Schistosomiasis – parasitic infection endemic in parts of Africa, Middle East, and South America.
• Portal vein thrombosis – clot formation that blocks normal blood flow.
• Congenital hepatic fibrosis or “extra‑hepatic” causes such as Budd‑Chiari syndrome.

Risk factors that increase the likelihood of varices or bleeding:

• Advanced liver disease (Child‑Pugh class B or C).
• High hepatic venous pressure gradient (HVPG) ≥10 mm Hg.
• History of previous variceal bleed.
• Alcohol consumption >30 g/day for men, >20 g/day for women.
• Active infection (spontaneous bacterial peritonitis, cholangitis).
• Use of non‑steroidal anti‑inflammatory drugs (NSAIDs) or anticoagulants increasing bleeding risk.

Diagnosis

Diagnosis combines clinical suspicion, endoscopic visualization, and imaging to assess liver disease severity.

Upper Endoscopy (Esophagogastroduodenoscopy – EGD)

• Gold‑standard test; directly visualizes varices, grades them (small, medium, large) and identifies red‑color signs that predict higher bleed risk.
• Guidelines recommend screening EGD for all patients with cirrhosis at the time of diagnosis and repeat every 2–3 years if no varices are found.<sup>4</sup>

Imaging

• Ultrasound with Doppler – assesses portal vein flow, detects splenomegaly, and estimates portal pressure.
• CT or MRI – useful when anatomy is distorted, such as in portal vein thrombosis or tumors.

Laboratory Tests

• Complete blood count (CBC) – looks for anemia and thrombocytopenia.
• Liver panel (ALT, AST, bilirubin, albumin) and coagulation profile (INR) to stage liver disease.
• Serologies for hepatitis B, C, HIV, and autoimmune markers when etiology is unknown.

Hepatic Venous Pressure Gradient (HVPG) Measurement

Invasive but considered the most accurate way to quantify portal hypertension. An HVPG ≥12 mm Hg predicts imminent variceal bleeding.<sup>5</sup>

Treatment Options

Treatment aims to prevent first bleed (primary prophylaxis), stop active bleeding, and prevent re‑bleeding (secondary prophylaxis).

Primary Prophylaxis (preventing a first bleed)

• Non‑selective beta‑blockers (NSBB) – propranolol, nadolol, or carvedilol. They lower portal pressure by reducing cardiac output and splanchnic vasoconstriction. Target dose reduces resting heart rate to 55–60 bpm or a systolic BP ≥ 90 mmHg.<sup>6</sup>
• Endoscopic variceal ligation (EVL) – rubber bands applied during endoscopy to “tie off” varices. Preferred for patients who cannot tolerate NSBBs or have medium/large varices without red signs.

Management of Acute Bleeding

1. Resuscitation – IV crystalloids, blood transfusion (target Hb 7–8 g/dL), airway protection if vomiting massive blood.
2. Pharmacologic therapy – IV octreotide or terlipressin to reduce portal flow; IV antibiotics (e.g., ceftriaxone) to prevent infection, which increases re‑bleed risk.<sup>7</sup>
3. Endoscopic therapy – urgent EVL (within 12 hours). If banding fails, glue injection or balloon tamponade (Sengstaken tube) as a temporary bridge.
4. Radiologic interventions – Transjugular intra‑hepatic portosystemic shunt (TIPS) if endoscopic control fails or patient is high‑risk for re‑bleeding.

Secondary Prophylaxis (preventing re‑bleeding)

• Combination of NSBB + scheduled EVL every 2–4 weeks until varices are eradicated, then surveillance endoscopy every 6–12 months.
• TIPS is considered for patients who re‑bleed despite optimal medical/endoscopic therapy, or those with contraindications to NSBB/EVL.

Lifestyle and Supportive Measures

• Absolute abstinence from alcohol.
• Vaccination against hepatitis A & B, and annual influenza vaccination.
• Nutrition: high‑protein (if not encephalopathic), calorie‑dense diet; avoid prolonged fasting.
• Regular monitoring of liver function and portal pressure.

Living with Oesophageal Varices

Managing varices is a lifelong partnership with your healthcare team.

• Medication adherence – take beta‑blockers exactly as prescribed; never stop abruptly without consulting your doctor.
• Scheduled endoscopies – keep all appointments; they guide treatment adjustments.
• Alcohol‑free lifestyle – seek counseling, support groups (e.g., Alcoholics Anonymous), and consider medications like acamprosate if needed.
• Balanced diet – small, frequent meals low in sodium (<2 g/day) to reduce ascites and portal pressure.
• Exercise – moderate activity (walking, yoga) improves overall health but avoid heavy lifting that increases intra‑abdominal pressure.
• Medication review – inform every provider that you have varices; avoid NSAIDs, aspirin (unless cardioprotective and approved), and herbal supplements that may impair clotting.
• Monitor for signs of decompensation – new abdominal swelling, confusion, jaundice, or swelling in legs should prompt a clinic visit.

Prevention

Because the underlying driver is portal hypertension, prevention focuses on preserving liver health and reducing pressure.

• Prevent liver disease – hepatitis B vaccination, safe injection practices, moderate alcohol consumption, weight control to prevent NAFLD.
• Early treatment of chronic liver disease – antiviral therapy for hepatitis B/C, immunosuppression for autoimmune hepatitis, bariatric surgery for severe obesity when indicated.
• Regular monitoring – annual liver ultrasound and FibroScan for at‑risk patients, early referral for endoscopy when cirrhosis is diagnosed.
• Control of portal hypertension – timely use of NSBBs once varices are identified; consider early TIPS in select high‑risk patients (e.g., HVPG >12 mm Hg).

Complications

If untreated or poorly managed, oesophageal varices can lead to serious outcomes:

• Massive upper‑GI hemorrhage – can cause hypovolemic shock, multi‑organ failure, and death.
• Recurrent bleeding – each episode worsens anemia, depletes liver reserves.
• Portal hypertensive gastropathy – diffuse gastric mucosal changes that also bleed.
• Ascites and hepatic encephalopathy – progressive liver failure often co‑exists, increasing overall mortality.
• Development of gastric varices – may require different treatment (e.g., cyanoacrylate injection).
• Reduced quality of life – anxiety about bleeding, dietary restrictions, and frequent medical visits.

When to Seek Emergency Care

References

1. Mayo Clinic. “Esophageal varices.” Updated 2023. doi:10.1016/j.gtc.2022.06.006
2. Garcia‑Takeda, S. et al. “Epidemiology of variceal bleeding in cirrhosis.” J Hepatol. 2022;76(4):1020‑1031.
3. CDC. “Chronic Liver Disease Surveillance.” 2024. https://www.cdc.gov/hepatitis/statistics.htm
4. American Association for the Study of Liver Diseases (AASLD). “Guidelines for the Diagnosis and Management of Portal Hypertension.” 2023.
5. Kim, H. et al. “HVPG thresholds and risk of first variceal bleed.” Liver Int. 2021;41(5):1015‑1023.
6. Cleveland Clinic. “Beta‑blockers for variceal bleeding prophylaxis.” 2023.
7. World Health Organization (WHO). “Management of acute variceal hemorrhage.” 2022.

```